PD-L1 (Fc fusion protein)

PD-L1, also known as B7-H1, is a member of the B7 family. PD-L, expressed on the tumor cells and/or stromal cells within the tumor microenvironment, interacts with PD-1, expressed on the surface of effector T cells, and attenuates the activation of the T cells. As such the inflammatory responses toward the tumor cells and infectious agents are compromised. P7101F and P701G contains human PD-L1 ECD fused to the mouse IgG2a and mouse IgG2a aglycoylated Fc domain, respectively.  Both PD-L1 Fc fusion proteins interact with PD-1 Fc fusion proteins (P7099F and P7099G each fused with wildtype mouse IgG2a Fc and aglycosylated mouse IgG2a Fc, respectively).

Interacting protein(s): PD-1 (P7099F, P7099G)
Related products: Checkpoint Proteins

For orders over 1 mg please inquire here.

Quick Spec

Description

PD-L1 also called B7-H1 as it was the first found homolog of B7-1 and B7-2(CD86) identified by searching human cDNA expressed tags and was subsequently found to be the ligand for PD-1. Like other proteins of B7 family, it contains the IgV and IgC domains in its extracellular region. The major function of PD-1 is to limit T cell activity during an inflammatory response to infection and to limit autoimmunity.

In this capacity, PD-1 regulates effector T cell activity and plays a critical role in resistance of tumor cells to immune surveillance. In contrast, CTLA-4 functions as a signal dampener for T cell activation. Engagement of PD-1 with its ligand (PD-L1 and PD-L2) triggers inhibitory signaling, diminishes cell proliferation and cytokine production. The PD-1/PDL1/PDL2 axis is therefore widely demonstrated to contribute to failed antitumor immunity. PD-L1 is expressed in many tumors and tumor cell line, and appears to be associated with poor outcomes in solid malignancy, while PD-1 expression by infiltrating T lymphocytes (TILs) also confers poor prognosis.

Interestingly, both Pd-1 deficient and wt-Pd-1 mice treated with anti PD-L1 antibody exhibited excellent rejection of PD-L1-expressing tumors. These observations suggestion a PD-1-dependent and a PD-1 independent pathway can be triggered by anti-PD-L1 antibody.

Amino Acid Sequence

References

1. Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10. Epub 20210107. doi: 10.1186/s13045-020-01027-5. PubMed PMID: 33413496; PubMed Central PMCID: PMC7792099.

2. Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021;12(9):2735-46. Epub 20210305. doi: 10.7150/jca.57334. PubMed PMID:

3. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Haidong Dong, Gefeng Zhu, Koji Tamada & Lieping Chen Nature Medicine 5:1365 - 1369 (1999)

4. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Fife B.T., Pauken K.E. Ann. N. Y. Acad. Sci. 1217:45-59 (2011)

5. The role of B7 family molecules in hematologic malignancy. Greaves P, Gribben JG. Blood. 121:734-44 (2013)